mHLA-DR在脓毒症免疫抑制中的作用
The Role of mHLA-DR in Sepsis Immunosuppression
DOI: 10.12677/acm.2024.14123221, PDF,    科研立项经费支持
作者: 杨金花：成都中医药大学医学与生命科学学院，四川 成都；夏洪韬*：遂宁市中心医院重症医学科，四川 遂宁
关键词: 脓毒症；免疫抑制；免疫监测；单核细胞HLA-DR；免疫治疗；Sepsis； Immunosuppression； Immunomonitoring； Monocyte Human Leukocyte Antigen-DR； Immunotherapy
摘要: 脓毒症是宿主对感染的反应失调而引起器官功能障碍的临床综合征，其发病率和死亡率在全球范围内居高不下。免疫抑制是造成脓毒症患者预后不良的关键阶段，导致患者继发感染易感性增加，ICU入住时间及总住院时间增加。免疫状态的评估是识别脓毒症患者免疫抑制和明确免疫调理治疗时机的重要前提，mHLA-DR是免疫功能监测的最佳生物标志物之一。本文就mHLA-DR对脓毒症免疫状态评估的作用，脓毒症免疫抑制机制及治疗方案进行综述。
Abstract: Sepsis is a clinical syndrome of organ dysfunction caused by a dysregulated host response to infection, with high morbidity and mortality worldwide. Immunosuppression is a critical stage contributing to the poor prognosis of sepsis patients, leading to increased susceptibility to secondary infections and increased ICU stay and total hospitalization time. Assessing immune status is an important prerequisite for identifying immunosuppression and clarifying the timing of immunome- odulatory therapy in sepsis patients. mHLA-DR is one of the best biomarkers for monitoring immune function. In this article, we review the role of mHLA-DR in assessing immune status in sepsis and the mechanism and treatment options of sepsis immunosuppression.
文章引用：杨金花, 夏洪韬. mHLA-DR在脓毒症免疫抑制中的作用[J]. 临床医学进展, 2024, 14(12): 1318-1325. https://doi.org/10.12677/acm.2024.14123221

参考文献

[1] Bauer, M., Gerlach, H., Vogelmann, T., Preissing, F., Stiefel, J. and Adam, D. (2020) Mortality in Sepsis and Septic Shock in Europe, North America and Australia between 2009 and 2019—Results from a Systematic Review and Meta-Analysis. Critical Care, 24, Article No. 239. [Google Scholar] [CrossRef] [PubMed]
[2] Singer, M., Deutschman, C.S., Seymour, C.W., Shankar-Hari, M., Annane, D., Bauer, M., et al. (2016) The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). Journal of the American Medical Association, 315, 801-810. [Google Scholar] [CrossRef] [PubMed]
[3] Rudd, K.E., Johnson, S.C., Agesa, K.M., Shackelford, K.A., Tsoi, D., Kievlan, D.R., et al. (2020) Global, Regional, and National Sepsis Incidence and Mortality, 1990-2017: Analysis for the Global Burden of Disease Study. The Lancet, 395, 200-211. [Google Scholar] [CrossRef] [PubMed]
[4] Evans, L., Rhodes, A., Alhazzani, W., Antonelli, M., Coopersmith, C.M., French, C., et al. (2021) Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock 2021. Intensive Care Medicine, 47, 1181-1247. [Google Scholar] [CrossRef] [PubMed]
[5] Gotts, J.E. and Matthay, M.A. (2016) Sepsis: Pathophysiology and Clinical Management. British Medical Journal, 353, i1585. [Google Scholar] [CrossRef] [PubMed]
[6] Chang, D.W., Tseng, C. and Shapiro, M.F. (2015) Rehospitalizations Following Sepsis. Critical Care Medicine, 43, 2085-2093. [Google Scholar] [CrossRef] [PubMed]
[7] Pei, F., Yao, R., Ren, C., Bahrami, S., Billiar, T.R., Chaudry, I.H., et al. (2022) Expert Consensus on the Monitoring and Treatment of Sepsis-Induced Immunosuppression. Military Medical Research, 9, Article No. 74. [Google Scholar] [CrossRef] [PubMed]
[8] 中国研究型医院学会休克与脓毒症专业委员会, 中国人民解放军重症医学专业委员会, 重症免疫研究协作组, 等. 脓毒症免疫抑制诊治专家共识[J]. 中华危重病急救医学, 2020, 32(11): 1281-1289.
[9] Sun, L., Wang, X., Saredy, J., Yuan, Z., Yang, X. and Wang, H. (2020) Innate-Adaptive Immunity Interplay and Redox Regulation in Immune Response. Redox Biology, 37, Article 101759. [Google Scholar] [CrossRef] [PubMed]
[10] Liu, D., Huang, S., Sun, J., Zhang, H., Cai, Q., Gao, C., et al. (2022) Sepsis-Induced Immunosuppression: Mechanisms, Diagnosis and Current Treatment Options. Military Medical Research, 9, Article No. 56. [Google Scholar] [CrossRef] [PubMed]
[11] Pfortmueller, C.A., Meisel, C., Fux, M. and Schefold, J.C. (2017) Assessment of Immune Organ Dysfunction in Critical Illness: Utility of Innate Immune Response Markers. Intensive Care Medicine Experimental, 5, Article No. 49. [Google Scholar] [CrossRef] [PubMed]
[12] Monneret, G., Lepape, A., Voirin, N., Bohé, J., Venet, F., Debard, A., et al. (2006) Persisting Low Monocyte Human Leukocyte Antigen-Dr Expression Predicts Mortality in Septic Shock. Intensive Care Medicine, 32, 1175-1183. [Google Scholar] [CrossRef] [PubMed]
[13] Leijte, G.P., Rimmelé, T., Kox, M., Bruse, N., Monard, C., Gossez, M., et al. (2020) Monocytic HLA-DR Expression Kinetics in Septic Shock Patients with Different Pathogens, Sites of Infection and Adverse Outcomes. Critical Care, 24, Article No. 110. [Google Scholar] [CrossRef] [PubMed]
[14] Landelle, C., Lepape, A., Voirin, N., Tognet, E., Venet, F., Bohé, J., et al. (2010) Low Monocyte Human Leukocyte Antigen-Dr Is Independently Associated with Nosocomial Infections after Septic Shock. Intensive Care Medicine, 36, 1859-1866. [Google Scholar] [CrossRef] [PubMed]
[15] Hagedoorn, N.N., Kolukirik, P., Nagtzaam, N.M.A., Nieboer, D., Verbruggen, S., Joosten, K.F., et al. (2021) Association of Monocyte HLA-DR Expression over Time with Secondary Infection in Critically Ill Children: A Prospective Observational Study. European Journal of Pediatrics, 181, 1133-1142. [Google Scholar] [CrossRef] [PubMed]
[16] Cajander, S., Tina, E., Bäckman, A., Magnuson, A., Strålin, K., Söderquist, B., et al. (2016) Quantitative Real-Time Polymerase Chain Reaction Measurement of HLA-DRA Gene Expression in Whole Blood Is Highly Reproducible and Shows Changes That Reflect Dynamic Shifts in Monocyte Surface HLA-DR Expression during the Course of Sepsis. PLOS ONE, 11, e0154690. [Google Scholar] [CrossRef] [PubMed]
[17] Zorio, V., Venet, F., Delwarde, B., Floccard, B., Marcotte, G., Textoris, J., et al. (2017) Assessment of Sepsis-Induced Immunosuppression at ICU Discharge and 6 Months after ICU Discharge. Annals of Intensive Care, 7, Article No. 80. [Google Scholar] [CrossRef] [PubMed]
[18] Pfortmueller, C.A., Meisel, C., Fux, M. and Schefold, J.C. (2017) Assessment of Immune Organ Dysfunction in Critical Illness: Utility of Innate Immune Response Markers. Intensive Care Medicine Experimental, 5, Article No. 49. [Google Scholar] [CrossRef] [PubMed]
[19] Döcke, W.D., Höflich, C., Davis, K.A., et al. (2005) Monitoring Temporary Immuno-Depression by Flow Cytometric Measurement of Monocytic HLA-DR Expression: A Multi-Center Standardized Study.
[20] Chen, Y. (2017) Dynamic Monitoring of Monocyte HLA-DR Expression for the Diagnosis Prognosis and Prediction of Sepsis. Frontiers in Bioscience, 22, 1344-1354. [Google Scholar] [CrossRef] [PubMed]
[21] Joshi, I., Carney, W.P. and Rock, E.P. (2023) Utility of Monocyte HLA-DR and Rationale for Therapeutic GM-CSF in Sepsis Immunoparalysis. Frontiers in Immunology, 14, Article 1130214. [Google Scholar] [CrossRef] [PubMed]
[22] Wu, J., Ma, J., Chen, J., Ou-Yang, B., Chen, M., Li, L., et al. (2011) Changes of Monocyte Human Leukocyte Antigen-Dr Expression as a Reliable Predictor of Mortality in Severe Sepsis. Critical Care, 15, Article No. R220. [Google Scholar] [CrossRef] [PubMed]
[23] Wu, J., Zhou, L., Liu, J., Ma, G., Kou, Q., He, Z., et al. (2013) The Efficacy of Thymosin Alpha 1 for Severe Sepsis (ETASS): A Multicenter, Single-Blind, Randomized and Controlled Trial. Critical Care, 17, Article No. R8. [Google Scholar] [CrossRef] [PubMed]
[24] Meisel, C., Schefold, J.C., Pschowski, R., Baumann, T., Hetzger, K., Gregor, J., et al. (2009) Granulocyte-Macrophage Colony-Stimulating Factor to Reverse Sepsis-Associated Immunosuppression. American Journal of Respiratory and Critical Care Medicine, 180, 640-648. [Google Scholar] [CrossRef] [PubMed]
[25] Hotchkiss, R.S., Monneret, G. and Payen, D. (2013) Sepsis-Induced Immunosuppression: From Cellular Dysfunctions to Immunotherapy. Nature Reviews Immunology, 13, 862-874. [Google Scholar] [CrossRef] [PubMed]
[26] Guo, Y., Patil, N.K., Luan, L., Bohannon, J.K. and Sherwood, E.R. (2017) The Biology of Natural Killer Cells during Sepsis. Immunology, 153, 190-202. [Google Scholar] [CrossRef] [PubMed]
[27] Fu, X. and Wang, Y. (2023) Interferon-γ Regulates Immunosuppression in Septic Mice by Promoting the Warburg Effect through the PI3K/Akt/mTOR Pathway. Molecular Medicine, 29, Article No. 95. [Google Scholar] [CrossRef] [PubMed]
[28] Döcke, W., Randow, F., Syrbe, U., Krausch, D., Asadullah, K., Reinke, P., et al. (1997) Monocyte Deactivation in Septic Patients: Restoration by IFN-Γ Treatment. Nature Medicine, 3, 678-681. [Google Scholar] [CrossRef] [PubMed]
[29] Borriello, F., Galdiero, M.R., Varricchi, G., Loffredo, S., Spadaro, G. and Marone, G. (2019) Innate Immune Modulation by GM-CSF and IL-3 in Health and Disease. International Journal of Molecular Sciences, 20, Article 834. [Google Scholar] [CrossRef] [PubMed]
[30] Flohé, S., Lendemans, S., Selbach, C., Waydhas, C., Ackermann, M., Schade, F.U., et al. (2003) Effect of Granulocyte-Macrophage Colony-Stimulating Factor on the Immune Response of Circulating Monocytes after Severe Trauma. Critical Care Medicine, 31, 2462-2469. [Google Scholar] [CrossRef] [PubMed]
[31] Hall, M.W., Knatz, N.L., Vetterly, C., Tomarello, S., Wewers, M.D., Volk, H.D., et al. (2010) Immunoparalysis and Nosocomial Infection in Children with Multiple Organ Dysfunction Syndrome. Intensive Care Medicine, 37, 525-532. [Google Scholar] [CrossRef] [PubMed]
[32] Francois, B., Jeannet, R., Daix, T., Walton, A.H., Shotwell, M.S., Unsinger, J., et al. (2018) Interleukin-7 Restores Lymphocytes in Septic Shock: The IRIS-7 Randomized Clinical Trial. JCI Insight, 3, e98960. [Google Scholar] [CrossRef] [PubMed]
[33] Akatsuka, M., Tatsumi, H., Sonoda, T. and Masuda, Y. (2021) Low Immunoglobulin G Level Is Associated with Poor Outcomes in Patients with Sepsis and Septic Shock. Journal of Microbiology, Immunology and Infection, 54, 728-732. [Google Scholar] [CrossRef] [PubMed]
[34] Pan, B., Sun, P., Pei, R., Lin, F. and Cao, H. (2023) Efficacy of IVIG Therapy for Patients with Sepsis: A Systematic Review and Meta-Analysis. Journal of Translational Medicine, 21, Article No. 765. [Google Scholar] [CrossRef] [PubMed]
[35] Li, C., Bo, L., Liu, Q. and Jin, F. (2015) Thymosin Alpha1 Based Immunomodulatory Therapy for Sepsis: A Systematic Review and Meta-Analysis. International Journal of Infectious Diseases, 33, 90-96. [Google Scholar] [CrossRef] [PubMed]
[36] Chang, K., Svabek, C., Vazquez-Guillamet, C., Sato, B., Rasche, D., Wilson, S., et al. (2014) Targeting the Programmed Cell Death 1: Programmed Cell Death Ligand 1 Pathway Reverses T Cell Exhaustion in Patients with Sepsis. Critical Care, 18, R3. [Google Scholar] [CrossRef] [PubMed]
[37] Hotchkiss, R.S., Colston, E., Yende, S., Crouser, E.D., Martin, G.S., Albertson, T., et al. (2019) Immune Checkpoint Inhibition in Sepsis: A Phase 1b Randomized Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Nivolumab. Intensive Care Medicine, 45, 1360-1371. [Google Scholar] [CrossRef] [PubMed]
[38] Watanabe, E., Nishida, O., Kakihana, Y., Odani, M., Okamura, T., Harada, T., et al. (2019) Pharmacokinetics, Pharmacodynamics, and Safety of Nivolumab in Patients with Sepsis-Induced Immunosuppression: A Multicenter, Open-Label Phase 1/2 Study. Shock, 53, 686-694. [Google Scholar] [CrossRef] [PubMed]
[39] Han, D., Shang, W., Wang, G., Sun, L., Zhang, Y., Wen, H., et al. (2015) Ulinastatin and Thymosin Α1-Based Immunomodulatory Strategy for Sepsis: A Meta-Analysis. International Immunopharmacology, 29, 377-382. [Google Scholar] [CrossRef] [PubMed]
[40] Liu, D., Yu, Z., Yin, J., Chen, Y., Zhang, H., Xin, F., et al. (2017) Effect of Ulinastatin Combined with Thymosin Alpha1 on Sepsis: A Systematic Review and Meta-Analysis of Chinese and Indian Patients. Journal of Critical Care, 39, 259-266. [Google Scholar] [CrossRef] [PubMed]

为你推荐